Pancreatic Cancer Research

ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years

Michael E. Feigin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8189-5568; OpenAlex author ID A5021466725. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
52
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 11

  1. Alprazolam Reduces Inflammatory Cytokine Production in Pancreatic Cancer-Associated Fibroblasts. Last author DOI 10.1158/2767-9764.crc-25-0472↗
  2. A targetable opioid/cancer associated fibroblast axis drives extracellular matrix remodeling and tumor aggressiveness in pancreatic cancer Last author DOI 10.64898/2026.05.20.726559↗
  3. Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-025-02408-5↗
  4. CPSF3 inhibition blocks pancreatic cancer cell proliferation through disruption of core histone mRNA processing. Last author DOI 10.1261/rna.079931.123↗
  5. Alternative Polyadenylation Characterizes Epithelial and Fibroblast Phenotypic Heterogeneity in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/cancers16030640↗
  6. Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-23-0547↗
  7. Drivers of Gene Expression Dysregulation in Pancreatic Cancer. Last author DOI 10.1016/j.trecan.2021.01.008↗
  8. Alternative polyadenylation drives oncogenic gene expression in pancreatic ductal adenocarcinoma. Last author DOI 10.1101/gr.257550.119↗
  9. Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ng.3861↗
  10. Challenges and Opportunities in Modeling Pancreatic Cancer. Co-author DOI 10.1101/sqb.2016.81.031104↗
  11. Organoid models of human and mouse ductal pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.12.021↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Swati Venkat · 5 shared papers, 2020–2024 · strength 1.12
  2. Kathryn E. Maraszek · 4 shared papers, 2023–2026 · strength 0.83
  3. Abdulrahman A. Alahmari · 4 shared papers, 2020–2024 · strength 0.67
  4. Hunter D. Reavis · 2 shared papers, 2026 · strength 0.51
  5. Nina G. Steele · 2 shared papers, 2023–2026 · strength 0.38
  6. Janusz Franco‐Barraza · 2 shared papers, 2023–2026 · strength 0.38
  7. Edna Cukierman · 2 shared papers, 2023–2026 · strength 0.38
  8. Abigail C. Cornwell · 2 shared papers, 2023–2024 · strength 0.33
  9. João A. Paulo · 1 shared paper, 2026 · strength 0.27
  10. Brooke Pereira · 1 shared paper, 2026 · strength 0.24
  11. Paul Timpson · 1 shared paper, 2026 · strength 0.24
  12. Kennedy S. Humphrey · 1 shared paper, 2025 · strength 0.23
  13. Katherine J. Crawford · 1 shared paper, 2025 · strength 0.23
  14. Vishnu Muthuraj Kumarasamy · 1 shared paper, 2025 · strength 0.23
  15. Erik S. Knudsen · 1 shared paper, 2025 · strength 0.23
  16. Agnieszka Katarzyna Witkiewicz · 1 shared paper, 2025 · strength 0.23
  17. Karen M. Mann · 1 shared paper, 2025 · strength 0.23
  18. Ethan V. Abel · 1 shared paper, 2025 · strength 0.23
  19. David Arthur Tuveson · 3 shared papers, 2015–2017 · strength 0.21
  20. Katerina V. Gurova · 1 shared paper, 2024 · strength 0.18
  21. Christos K Fountzilas · 1 shared paper, 2023 · strength 0.15
  22. H. Carlo Maurer · 1 shared paper, 2020 · strength 0.12
  23. Kenneth P. Olive · 1 shared paper, 2020 · strength 0.12
  24. Peter J. Bailey · 1 shared paper, 2017 · strength 0.06
  25. Sean Michael Grimmond · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.